Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business -- To Accelerate U.S. Market

• Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.ai
• To strengthen revenue growth of AI-based brain imaging solutions in the North American market and expand product deployment across healthcare institutions

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 2nd that it has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

Josh Cohen, newly appointed Head of Americas, brings over a decade of expertise in sales and commercialization strategy within the medical AI sector. He has honed his skills through leadership roles in global sales and marketing at top-tier medical device companies, including Philips—one of the world's leading medical imaging manufacturers—as well as Cortechs.ai, Shared Imaging, and most recently has worked as the acting Chief Commercial Officer (CCO) with MRI AI-based technology companies to launch and scale in the US and abroad.

Josh Cohen previously served as CCO at Cortechs.ai, one of Neurophet's global rivals, where he spearheaded the growth of key AI-driven brain imaging analysis products and led the company's expansion across international markets. Cortechs.ai specializes in AI-based medical imaging analysis software and directly competes with Neurophet in the Americas region.

Neurophet, market leader in the Asia Pacific region, is now focused on accelerating its entry into the Americas with this key appointment. Having led the execution of global commercialization strategies at a leading AI brain imaging analysis company, Josh Cohen will now build the team, the operations, and the customer success for Neurophet in the Americas.

With patients, clinicians, and customer satisfaction at the forefront, Neurophet aims to drive revenue growth, establish distribution partnerships, and implement market entry strategies across Canada, the United States, and South America.

Josh Cohen, Head of Americas Business at Neurophet, stated "I am delighted to be part of Neurophet, a company with global competitiveness in the field of imaging analysis related to Alzheimer's disease treatment prescriptions and look forward to accelerating product sales by strengthening our entry into the North American market."

Jake Junkil Been, Co-CEO of Neurophet, said "With Josh Cohen joining us, the pivotal leader behind the rapid growth of our key competitor Cortechs.ai, Neurophet is well-positioned to accelerate product deployment throughout the North American market. Looking ahead, we aim to expand our product offerings with a strong focus on major healthcare institutions across the United States."

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

• Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.ai
• To strengthen revenue growth of AI-based brain imaging solutions in the North American market and expand product deployment across healthcare institutions

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 2nd that it has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

Josh Cohen, newly appointed Head of Americas, brings over a decade of expertise in sales and commercialization strategy within the medical AI sector. He has honed his skills through leadership roles in global sales and marketing at top-tier medical device companies, including Philips—one of the world's leading medical imaging manufacturers—as well as Cortechs.ai, Shared Imaging, and most recently has worked as the acting Chief Commercial Officer (CCO) with MRI AI-based technology companies to launch and scale in the US and abroad.

Josh Cohen previously served as CCO at Cortechs.ai, one of Neurophet's global rivals, where he spearheaded the growth of key AI-driven brain imaging analysis products and led the company's expansion across international markets. Cortechs.ai specializes in AI-based medical imaging analysis software and directly competes with Neurophet in the Americas region.

Neurophet, market leader in the Asia Pacific region, is now focused on accelerating its entry into the Americas with this key appointment. Having led the execution of global commercialization strategies at a leading AI brain imaging analysis company, Josh Cohen will now build the team, the operations, and the customer success for Neurophet in the Americas.

With patients, clinicians, and customer satisfaction at the forefront, Neurophet aims to drive revenue growth, establish distribution partnerships, and implement market entry strategies across Canada, the United States, and South America.

Josh Cohen, Head of Americas Business at Neurophet, stated "I am delighted to be part of Neurophet, a company with global competitiveness in the field of imaging analysis related to Alzheimer's disease treatment prescriptions and look forward to accelerating product sales by strengthening our entry into the North American market."

Jake Junkil Been, Co-CEO of Neurophet, said "With Josh Cohen joining us, the pivotal leader behind the rapid growth of our key competitor Cortechs.ai, Neurophet is well-positioned to accelerate product deployment throughout the North American market. Looking ahead, we aim to expand our product offerings with a strong focus on major healthcare institutions across the United States."

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business -- To Accelerate U.S. Market

TOKYO, April 2, 2026 /PRNewswire/ -- GA technologies Co., Ltd. (Headquarters: Minato-ku, Tokyo; President, CEO: Ryo Higuchi; Stock Code: 3491; hereinafter referred to as the "Company") announces that its AI real estate investment service, "RENOSY," has launched an initiative to rebrand "Renters Warehouse" (operated by RW OpCo, LLC [Headquarters: United States], a Group company), as "RENOSY by Renters Warehouse."

URL: https://www.renterswarehouse.com/

• Background and Outlook of the Brand Integration and Renewal

Since its founding in 2013, the Company has operated under its corporate philosophy:

"Spark excitement and inspiration by fusing technology with innovation to propel the world forward." The Company's core business is the AI real estate investment service "RENOSY," which leverages technology to provide unique one-stop services for property purchase, management, and sale.

RW OpCo, LLC, founded in 2007, operates the real estate investment marketplace "Renters Warehouse." Primarily serving individuals and institutional investors in the United States, the platform functions as an online marketplace and currently operates in 18 states and 31 locations across the country.

The Company completed the consolidation of RW OpCo, LLC as a subsidiary in March 2024 and began providing real estate services in the U.S. market.^[1] Since the fiscal year ending October 2025, the business has maintained strong performance, achieving quarterly profitability and growing rapidly to become the Company's third pillar of profit.^[2]

The Company has now moved to rebrand its U.S. business from "Renters Warehouse" to "RENOSY by Renters Warehouse," aiming to drive further growth in the U.S. market and maximize group synergies. Through the full-scale expansion of "RENOSY" in the U.S. market, the Company looks to promote the adoption of services that enable reliable, seamless, and optimal asset formation through real estate in the country.

The impact of this matter on the Company's business results is insignificant.

• AI Real Estate Investment RENOSY

RENOSY is an AI real estate investment service that utilizes technology. Reliable, seamless, and optimal asset-building through real estate is realized by providing one-stop support for the purchase, management, and sale of property, maximizing operational effectiveness. An extensive product lineup is offered that includes condominiums, apartments, and detached houses, etc. Surveys conducted by Tokyo Shoko Research have ranked RENOSY No. 1 in Japan in real estate investment sales and purchases.^[3]